The role of subcutaneous infusion of apomorphine in Parkinson’s disease

References

• Colosimo C, De Michele M. Motor fluctuations in Parkinson’s disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21
   PubMed Web of Science ®Google Scholar
• Golbe LI. Young-onset Parkinson’s disease: a clinical review. Neurology 1991;41(2(Pt 1):168-73
   PubMedGoogle Scholar
• Olanow CW, Gracies JM, Goetz CG, et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson’s disease: a double blind video-based analysis. Mov Disord 2009;24(3):336-43
   PubMedGoogle Scholar
• Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002;59(3):408-13
   PubMed Web of Science ®Google Scholar
• Obeso JA, Rodriguez-Oroz M, Marin C, et al. The origin of motor fluctuations in Parkinson’s disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004;62(1 Suppl 1):S17-30
   PubMed Web of Science ®Google Scholar
• Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson’s disease. Parkinsonism Relat Disord 2009;15(Suppl 4):S18-23
   Google Scholar
• Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005;20(8):919-31
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002;41(4):261-309
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobility. Neurology 1988;38(3):419-21
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26(3):156-63
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery? J Neural Transm 2013;120(9):1305-20
   PubMed Web of Science ®Google Scholar
• Jenner P. Dopamine agonists in Parkinson’s disease--focus on non-motor symptoms. Eur J Neurol 2008;15(Suppl 2):1
   PubMedGoogle Scholar
• Nutt JG. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of L-DOPA. Adv Neurol 1996;69:493-6
   PubMedGoogle Scholar
• Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006;7(4):295-309
   PubMed Web of Science ®Google Scholar
• Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson’s disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997;20(2):95-115
   PubMedGoogle Scholar
• Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain 2002;125(Pt 9):2058-66
   PubMedGoogle Scholar
• Matthiessen A. Research into the chemical constitution of the opium bases. Part I: on the action of hydrochloric acid on morphia. Proc R Soc Lond B Biol SC 1869;17:455-60
   Google Scholar
• Colosimo C, Merello M, Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin Neuropharmacol 1994;17(3):243-59
   PubMed Web of Science ®Google Scholar
• Weill E. De l’apomorphine dans certain troubles nerveux. Lyon Med 1884;48:411-19
   Google Scholar
• Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc 1951;56:251-3
   PubMedGoogle Scholar
• Cotzias GC, Papavasiliou PS, Fehling C, et al. Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med 1970;282(1):31-3
   PubMed Web of Science ®Google Scholar
• Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet 1979;1(8123):954-6
   PubMed Web of Science ®Google Scholar
• Merello M, Pirtosek Z, Bishop S, Lees AJ. Cardiovascular reflexes in Parkinson’s disease: effect of domperidone and apomorphine. Clin Auton Res 1992;2(4):215-19
   PubMedGoogle Scholar
• Przedborski S, Levivier M, Raftopoulos C, et al. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord 1995;10(1):28-36
   PubMedGoogle Scholar
• Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26(2):232-8
   PubMed Web of Science ®Google Scholar
• Nicolle E, Pollak P, Serre-Debeauvais F, et al. Pharmacokinetics of apomorphine in parkinsonian patients. Fundam Clin Pharmacol 1993;7(5):245-52
   PubMedGoogle Scholar
• Harder S, Baas H, Demisch L, Simon E. Dose response and concentration response relationship of apomorphine in patients with Parkinson’s disease and end-of-dose akinesia. Int J Clin Pharmacol Ther 1998;36(7):355-62
   PubMedGoogle Scholar
• Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson’s disease: clinical and pharmacokinetic observations. Brain 2001;124(Pt 2):331-40
   PubMedGoogle Scholar
• van der Geest R, van Laar T, Kruger PP, et al. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson’s disease. Clin Neuropharmacol 1998;21(3):159-68
   PubMed Web of Science ®Google Scholar
• Kapoor R, Turjanski N, Frankel J, et al. Intranasal apomorphine: a new treatment in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990;53(11):1015
   PubMed Web of Science ®Google Scholar
• Lees AJ, Montastruc JL, Turjanski N, et al. Sublingual apomorphine and Parkinson’s disease. J Neurol Neurosurg Psychiatry 1989;52(12):1440
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Bishop S, Lees AJ, et al. Rectal apomorphine in Parkinson’s disease. Lancet 1991;337(8733):118
   PubMedGoogle Scholar
• Grosset KA, Malek N, Morgan F, Grosset DG. Phase IIa randomized double-blind, placebo-controlled study of inhaled apomorphine as acute challenge for rescuing ‘off’ periods in patients with established Parkinson’s disease. Eur J Neurol 2013;20(11):1445-50
   PubMed Web of Science ®Google Scholar
• Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988;1(8582):403-6
   PubMed Web of Science ®Google Scholar
• Poewe W, Kleedorfer B, Wagner M, et al. Side-effects of subcutaneous apomorphine in Parkinson’s disease. Lancet 1989;1(8646):1084-5
   PubMedGoogle Scholar
• Kempster PA, Iansek R, Larmour I. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations. Aust N Z J Med 1991;21(3):314-18
   PubMedGoogle Scholar
• Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord 1993;8(2):165-70
   PubMed Web of Science ®Google Scholar
• Merello M, Leiguarda R. [Treatment of motor fluctuations in Parkinson’s disease with subcutaneous injections of apomorphine]. Medicina (B Aires) 1995;55(1):5-10
   PubMedGoogle Scholar
• Ostergaard L, Werdelin L, Odin P, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;58(6):681-7
   PubMed Web of Science ®Google Scholar
• Esteban Munoz J, Marti MJ, Marin C, Tolosa E. Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations. Clin Neuropharmacol 1997;20(3):245-52
   PubMedGoogle Scholar
• Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65(5):709-16
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001;58(9):1385-92
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton R. UPDRS program members. Unified Parkinson’s Disease Rating Scale. In: Recent developments in Parkinsons disease. Fahn S, Marsden CD, Goldstein M, Calne DB, editors. Macmillan Healthcare Information; Florham Park, NJ,USA: 1987. 153-63
   Google Scholar
• Verhagen Metman L, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson’s disease and the pathogenesis of motor complications. Neurology 1997;48(2):369-72
   PubMedGoogle Scholar
• Pfeiffer RF, Gutmann L, Hull KL Jr, et al. Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord 2007;13(2):93-100
   PubMed Web of Science ®Google Scholar
• Stacy M. Apomorphine: north American clinical experience. Neurology 2004;62(6 Suppl 4):S18-21
   Google Scholar
• Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 2007;258(1-2):137-43
   PubMed Web of Science ®Google Scholar
• Trosch RM, Silver D, Bottini PB. Intermittent subcutaneous apomorphine therapy for ’off’ episodes in Parkinson’s disease: a 6-month open-label study. CNS Drugs 2008;22(6):519-27
   PubMed Web of Science ®Google Scholar
• Isaacson SH, Chaudhuri KR. Morning akinesia and the potential role of gastroparesis – managing delayed onset of first daily dose of oral levodopa in patients with Parkinson’s disease. Eur Neurol Rev 2013;8(2):82-4
   Google Scholar
• Grandas F. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease. Expert Rev Neurother 2013;13(12):1343-53
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 2005;20(2):151-7
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson’s disease with motor fluctuations: a multicenter study. Mov disord 2008;23(8):1130-6
   PubMed Web of Science ®Google Scholar
• Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998;64(5):573-6
   PubMed Web of Science ®Google Scholar
• Stocchi F, Bramante L, Monge A, et al. Apomorphine and lisuride infusion. A comparative chronic study. Adv Neurol 1993;60:653-5
   PubMedGoogle Scholar
• Chaudhuri KR, Critchley P, Abbott RJ, et al. Subcutaneous apomorphine for on-off oscillations in Parkinson’s disease. Lancet 1988;2(8622):1260
   PubMed Web of Science ®Google Scholar
• Morgante L, Basile G, Epifanio A, et al. Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson’s disease: a follow-up of two years. Arch Gerontol Geriatr Suppl 2004(9):291-6
   PubMedGoogle Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord 2002;17(6):1235-41
   PubMed Web of Science ®Google Scholar
• Kanovsky P, Kubova D, Bares M, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 2002;17(1):188-91
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011;258(4):579-85
   PubMed Web of Science ®Google Scholar
• Alegret M, Valldeoriola F, Marti M, et al. Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson’s disease. Mov Disord 2004;19(12):1463-9
   PubMed Web of Science ®Google Scholar
• . ECDEU Assessment Manual for Psychopharmacology, revised. editors. Guy WWashington D. US Department of Health, Education and Welfare, US Government Printing Office; Washington DC, USA: 1976
   Google Scholar
• Goetz CG, Nutt JG, Stebbins GT. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile. Mov Disord 2008;23(16):2398-403
   PubMed Web of Science ®Google Scholar
• Fox SH, Henry B, Hill MP, et al. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001;16(4):642-50
   PubMed Web of Science ®Google Scholar
• Di Rosa AE, Epifanio A, Antonini A, et al. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson’s disease. Neurol 2003;24(3):174-5
   Google Scholar
• Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 2011;1(2):197-203
   PubMedGoogle Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 2007;22(13):1901-11
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 1997;26(5):353-7
   PubMed Web of Science ®Google Scholar
• Reddy P, Martinez-Martin P, Odin P, et al. A multicenter European comparative survey of motor and non motor effects of subcutaneous apomorphine infusion and intrajejunal levodopa infusion in Parkinson’s disease (The EuroInf survey). [abstract]. Mov Disord 2013;28(Suppl 1):596
   Google Scholar
• Ray-Chaudhuri K, Abbott RJ, Millac PA. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment. J Neurol Neurosurg Psychiatry 1991;54(4):372-3
   PubMedGoogle Scholar
• Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord 1997;3(2):103-7
   PubMedGoogle Scholar
• Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-14
   PubMed Web of Science ®Google Scholar
• van Laar T, Postma AG, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson’s disease and pre-existing visual hallucinations. Parkinsonism Relat Disord 2010;16(1):71-2
   PubMed Web of Science ®Google Scholar
• Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71
   PubMed Web of Science ®Google Scholar
• Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;799-812
   Google Scholar
• Geerligs L, Meppelink AM, Brouwer WH, van Laar T. The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study. Clin Neuropharmacol 2009;32(5):266-8
   PubMed Web of Science ®Google Scholar
• Drapier S, Gillioz AS, Leray E, et al. Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord 2012;18(1):40-4
   PubMed Web of Science ®Google Scholar
• De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006;77(4):450-3
   PubMed Web of Science ®Google Scholar
• Naidu Y, Logishetty K, Martin A. Efficacy of apomorphine infusion on mood and depression aspects on non-motor symptoms in advanced Parkinson’s disease. Park Rel Disord 2009;15(Suppl 2):130
   Google Scholar
• Todorova A, Ray Chaudhuri K. Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2013;19(12):1073-8
   PubMed Web of Science ®Google Scholar
• Reuter I, Ellis CM, Ray Chaudhuri K. Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurol Scand 1999;100(3):163-7
   PubMed Web of Science ®Google Scholar
• Tribl GG, Sycha T, Kotzailias N, et al. Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry 2005;76(2):181-5
   PubMed Web of Science ®Google Scholar
• Garcia Ruiz PJ. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson’s disease. Mov Disord 2006;21(5):727-8
   PubMed Web of Science ®Google Scholar
• Factor SA, Brown DL, Molho ES. Subcutaneous apomorphine injections as a treatment for intractable pain in Parkinson’s disease. Mov Disord 2000;15(1):167-9
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol 1993;33(5):490-3
   PubMed Web of Science ®Google Scholar
• Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2(8626-8627):1451-3
   PubMedGoogle Scholar
• Tyne HL, Parsons J, Sinnott A, et al. A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease. J Neurol 2004;251(11):1370-4
   PubMed Web of Science ®Google Scholar
• Todd A, James CA. Apomorphine nodules in Parkinson’s disease: best practice considerations. Br J Community Nurs 2008;13(10):457-63
   PubMedGoogle Scholar
• Poltawski L, Edwards H, Todd A, et al. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord 2009;24(1):115-18
   PubMedGoogle Scholar
• Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. BMJ 2002;324(7352):1483-7
   PubMedGoogle Scholar
• Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother 2009;9(6):859-67
   PubMed Web of Science ®Google Scholar
• Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1990;53(2):96-101
   PubMed Web of Science ®Google Scholar
• Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol Gen 1935;18:643-62
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Nyholm D, Constantinescu R, Holmberg B, et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations. Acta Neurol Scand 2009;119(5):345-8
   PubMed Web of Science ®Google Scholar
• Hilker R, Antonini A, Odin P. What is the best treatment for fluctuating Parkinson’s disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm 2011;118(6):907-14
   PubMedGoogle Scholar
• Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 2006;355(9):896-908
   PubMed Web of Science ®Google Scholar
• Saint-Cyr JA, Trepanier LL, Kumar R, et al. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson’s disease. Brain 2000;123(Pt 10):2091-108
   PubMed Web of Science ®Google Scholar
• Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease--long-term experience. Acta Neurol Scand 2001;104(6):343-8
   PubMed Web of Science ®Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64(2):216-23
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24(10):1468-74
   PubMed Web of Science ®Google Scholar
• Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review. J Neurol 2013;260(11):2701-14
   PubMed Web of Science ®Google Scholar
• Schupbach MW, Welter ML, Bonnet AM, et al. Mortality in patients with Parkinson’s disease treated by stimulation of the subthalamic nucleus. Mov Disord 2007;22(2):257-61
   PubMedGoogle Scholar
• Hagell P, Odin P. Apomorphine in the treatment of Parkinson’s disease. J Neurosci Nurs 2001;33(1):21-34.37-8
   PubMedGoogle Scholar
• Castano B, Mateo D, Gimenez-Roldan S. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson’s disease patients on an out-patient basis: experience and recommendations]. Neurologia 2007;22(3):133-7
   PubMed Web of Science ®Google Scholar
• Bowron A. Practical considerations in the use of apomorphine injectable. Neurology 2004;62(6 Suppl 4):S32-6
   Google Scholar
• Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67(1):58-63
   PubMedGoogle Scholar